{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:41:42Z","timestamp":1783690902429,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00417-021-05504-6","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T07:00:52Z","timestamp":1638342052000},"page":"1633-1639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Intravitreal fluocinolone acetonide 0.19\u00a0mg (Iluvien\u00ae) for the treatment of uveitic macular edema: 2-year follow-up of 20 patients"],"prefix":"10.1007","volume":"260","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8463-8359","authenticated-orcid":false,"given":"Anne","family":"Studsgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e5re \u00d8rts","family":"Clemmensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Slot","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,1]]},"reference":[{"key":"5504_CR1","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.ophtha.2006.03.027","volume":"113","author":"CWTA Lardenoye","year":"2006","unstructured":"Lardenoye CWTA, van Kooij B, Rothova A (2006) Impact of macular edema on visual acuity in uveitis. Ophthalmology 113:1446\u20131449. https:\/\/doi.org\/10.1016\/j.ophtha.2006.03.027","journal-title":"Ophthalmology"},{"key":"5504_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/09273948.2019.1576910","volume":"27","author":"M Accorinti","year":"2019","unstructured":"Accorinti M, Okada AA, Smith JR, Gilardi M (2019) Epidemiology of macular edema in uveitis. Ocul Immunol Inflamm 27:169\u2013180. https:\/\/doi.org\/10.1080\/09273948.2019.1576910","journal-title":"Ocul Immunol Inflamm"},{"key":"5504_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s40135-016-0090-3","volume":"4","author":"R Goldhardt","year":"2016","unstructured":"Goldhardt R, Rosen BS (2016) Uveitic macular edema: treatment update. Current ophthalmology reports 4:30\u201337. https:\/\/doi.org\/10.1007\/s40135-016-0090-3","journal-title":"Current ophthalmology reports"},{"key":"5504_CR4","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/DDDT.S166092","volume":"13","author":"S Koronis","year":"2019","unstructured":"Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos PG (2019) Update in treatment of uveitic macular edema. Drug Des Dev Ther 13:667\u2013680. https:\/\/doi.org\/10.2147\/DDDT.S166092","journal-title":"Drug Des Dev Ther"},{"key":"5504_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","volume":"125","author":"AD Dick","year":"2018","unstructured":"Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort RJ, Brezin AP, Chee SP, Davis JL, Ramanan AV, Sonoda K-H, Carreno E, Nascimento H, Salah S, Salek S, Siak J, Steeples L (2018) Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) initiative. Ophthalmology 125:757\u2013773. https:\/\/doi.org\/10.1016\/j.ophtha.2017.11.017","journal-title":"Ophthalmology"},{"key":"5504_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s40135-017-0134-3","volume":"5","author":"JR de Oliveira Dias","year":"2017","unstructured":"de Oliveira Dias JR, Nunes RP, Goldhardt R (2017) New drugs and new posterior delivery methods in CME. Current ophthalmology reports 5:160\u2013168. https:\/\/doi.org\/10.1007\/s40135-017-0134-3","journal-title":"Current ophthalmology reports"},{"key":"5504_CR7","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/164692","volume":"2014","author":"M Cabrera","year":"2014","unstructured":"Cabrera M, Yeh S, Albini TA (2014) Sustained-release corticosteroid options Journal of ophthalmology 2014:164692. https:\/\/doi.org\/10.1155\/2014\/164692","journal-title":"Sustained-release corticosteroid options Journal of ophthalmology"},{"key":"5504_CR8","unstructured":"Alimera Sciences Continues to Execute on Its Expansion. https:\/\/www.globenewswire.com\/fr\/news-release\/2021\/03\/17\/2194502\/0\/en\/Alimera-Sciences-Continues-to-Execute-on-Its-Expansion-Strategy-in-Denmark-and-Luxembourg-and-Achieves-Extended-Reimbursement-in-Ireland.html. Accessed 29 Jun 2021"},{"key":"5504_CR9","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.ophtha.2020.04.001","volume":"127","author":"GJ Jaffe","year":"2020","unstructured":"Jaffe GJ, Pavesio CE (2020) Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: three-year results. Ophthalmology 127:1395\u20131404. https:\/\/doi.org\/10.1016\/j.ophtha.2020.04.001","journal-title":"Ophthalmology"},{"key":"5504_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/09273948.2016.1215472","volume":"26","author":"AK Reddy","year":"2018","unstructured":"Reddy AK, Burkholder BM, Khan IR, Thorne JE (2018) Iluvien implantation for uveitis and uveitic macular edema. Ocul Immunol Inflamm 26:315\u2013316. https:\/\/doi.org\/10.1080\/09273948.2016.1215472","journal-title":"Ocul Immunol Inflamm"},{"key":"5504_CR11","doi-asserted-by":"publisher","unstructured":"Meira J, Madeira C, Falcao-Reis F, Figueira L (2019) Sustained control from recurring non-infectious uveitic macular edema with 0.19 mg fluocinolone acetonide intravitreal implant - a case report. Ophthalmology and therapy. https:\/\/doi.org\/10.1007\/s40123-019-00209-w","DOI":"10.1007\/s40123-019-00209-w"},{"key":"5504_CR12","doi-asserted-by":"publisher","unstructured":"Weber LF, Marx S, Auffarth GU, Scheuerle AF, Tandogan T, Mayer C, Khoramnia R (2019) Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema. Journal of ophthalmic inflammation and infection 9:3 . https:\/\/doi.org\/10.1186\/s12348-019-0168-9","DOI":"10.1186\/s12348-019-0168-9"},{"key":"5504_CR13","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2147\/OPTH.S216912","volume":"15","author":"LR Steeples","year":"2021","unstructured":"Steeples LR, Pockar S, Jones NP, Leal I (2021) Evaluating the safety, efficacy and patient acceptability of intravitreal fluocinolone acetonide (0.2mcg\/day) implant in the treatment of non-infectious uveitis affecting the posterior segment. Clinical ophthalmology (Auckland, NZ) 15:1433\u20131442. https:\/\/doi.org\/10.2147\/OPTH.S216912","journal-title":"Clinical ophthalmology (Auckland, NZ)"},{"key":"5504_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40123-020-00328-9","volume":"10","author":"AS Ansari","year":"2021","unstructured":"Ansari AS, Amir Z, Williams GS (2021) Bilateral 0.19 mg fluocinolone acetonide intravitreal implant in the successful treatment of juvenile idiopathic arthritis-associated uveitis and secondary macular oedema: a case report and review of intravitreal therapies. Ophthalmol Therapy 10:193\u2013200. https:\/\/doi.org\/10.1007\/s40123-020-00328-9","journal-title":"Ophthalmol Therapy"},{"key":"5504_CR15","doi-asserted-by":"publisher","unstructured":"Ajamil-Rodanes S, Testi I, Luis J, Robson AG, Westcott M, Pavesio C (2020) Evaluation of fluocinolone acetonide 0.19 mg intravitreal implant in the management of birdshot retinochoroiditis. The British journal of ophthalmology. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317372","DOI":"10.1136\/bjophthalmol-2020-317372"},{"key":"5504_CR16","doi-asserted-by":"publisher","unstructured":"Hikal M, Celik N, Auffarth GU, Kessler LJ, Mayer CS, Khoramnia R (2021) Intravitreal 0.19 mg fluocinolone acetonide implant in non-infectious uveitis. Journal of clinical medicine 10. https:\/\/doi.org\/10.3390\/jcm10173966","DOI":"10.3390\/jcm10173966"},{"key":"5504_CR17","doi-asserted-by":"publisher","unstructured":"Pockar S, Leal I, Chhabra R, Jones NP, Steeples LR (2021) Intravitreal fluocinolone 0.19mg implant in the management of chronic non-infectious uveitis: 12-month outcomes from a single tertiary centre. Ocular immunology and inflammation 1\u20137\u00a0https:\/\/doi.org\/10.1080\/09273948.2021.1922707","DOI":"10.1080\/09273948.2021.1922707"},{"key":"5504_CR18","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ophtha.2018.10.033","volume":"126","author":"GJ Jaffe","year":"2019","unstructured":"Jaffe GJ, Foster CS, Pavesio CE, Paggiarino DA, Riedel GE (2019) Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology 126:601\u2013610. https:\/\/doi.org\/10.1016\/j.ophtha.2018.10.033","journal-title":"Ophthalmology"},{"key":"5504_CR19","unstructured":"Prescribing Information - ILUVIEN. https:\/\/iluvien.co.uk\/prescribing-information\/. Accessed 1 Jul 2021"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05504-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05504-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05504-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T10:12:31Z","timestamp":1649931151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05504-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,1]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["5504"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05504-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,1]]},"assertion":[{"value":"2 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed were in accordance with the ethical standards of the Department of Ophthalmology, Aarhus University Hospital, Denmark, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent to treatment with Iluvien\u00ae was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable (treatment quality assessment).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}